

NexoBrid®


Validated & commercialized

Globally approved: FDA, EU, JP, IN; 12,000 patients



Clear Unmet Need for **Early, Effective and Selective Non-Surgical Eschar Removal** in Severe Burns

Eschar Removal is the **1st Critical Step** in Burn Care




Prevents local infection and sepsis

Avoids further deterioration and scarring

Enables initiation of wound healing

Allows visual assessment of wound bed

Current Practice is **Traumatic & non-selective**



Loss of healthy tissue & blood

Challenging in delicate areas

Requires surgical team, operating room

NexoBrid significantly reduces need for surgery & improves patient outcomes
Provides a disruptive Bioactive Therapy for Burn Care



Before



After

NexoBrid

- A sterile mixture of proteolytic enzymes
- Easy to use, topical application, effectively removes eschar within 4 hours without harming viable tissue or blood loss
- Allows for early visual assessment of the wound

